"uuid:ID","text","id","label","name","instanceType","description"
"8d7463f8-f55f-417f-80fc-618f7ccb9b20","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","Objective_1","","OBJ1","Objective","Main objective"
"498749c9-8f8d-4d51-ac42-87eac2d5b21c","To document the safety profile of the xanomeline TTS.","Objective_2","","OBJ2","Objective","Safety"
"674ebde5-b6a3-45d4-bb0a-65ae2d21cd28","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","Objective_3","","OBJ3","Objective","Behaviour"
"426e8d65-f9a3-414b-82ed-671f0da77872","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","Objective_4","","OBJ4","Objective",""
"2ff171d4-ea7d-48e6-bd3d-9baa8803c3ab","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","Objective_5","","OBJ5","Objective",""
"d55fbbe4-a225-46b2-a1d7-46726084d01b","To assess the treatment response as a function of Apo E genotype.","Objective_6","","OBJ6","Objective",""
